The evolution of different branches of medicine as experimental disciplines has depended on the ability to manipulate cell population and organ functions under controlled conditions1. Such ability has its roots in the availability of measurable models able to recapitulate processes happening in our body.
In the age of immunotherapy and single-cell genomic profiling2, cancer biology needs to take advantage of emerging in vitro and computational models for investigating the tumor-immune interface in a proper spatiotemporal context2,3.
The tumor microenvironment4 (TME) is a complex tissue where cancer cells continuously interact and dynamically co-evolve with the other cellular (immune, stromal, and endothelial cells) and non-cellular (the extracellular matrix, ECM) components. The dynamic nature of this complex landscape dictates whether immune cells play as friends or foes of malignant cells, thus strongly affecting both disease progression and response to therapy. Nowadays, great efforts from onco-immunologists, bioinformaticians, and systems biology experts are converging to address the clinical significance of cancer heterogeneity5,6, either in the space (i.e., in distinct tumoral regions) and time (i.e., at distinct tumor progression stages)5,6, and to characterize cancer and immune cell phenotype and function at a single-cell level. As an example of this synergy, advanced computer-vision techniques are now routinely used for spatial mapping of immune infiltrate in histological samples7,8.
On the front of experimental models, bridging animal studies and traditional in vitro methods, advances in microfluidics and co-culturing techniques give access to different classes of micro-engineered cellular models such as organoids, micro-physiological systems9,10,11 (MPS), and organs-on-chip12,13,14 (OOC). They share the common trait to zoom in the 'big picture' view of the cellular ecosystems and expanding the in vitro potential to control microenvironmental factors while exploiting high-content microscopy15 and image processing approaches.
Nowadays, state-of-the-art- MPS and OOC systems have begun to include immunological aspects , incorporating different subtypes of immune cells in existing tissues- and co-cultures, so to explore and measure a variety of processes like inflammatory diseases, wound healing, mucosal immunity, and response to toxins or daily food products16. TME-on-a-chip models10,11,12,13,14,15,16,17, also integrated with perfusable microvessels18,19,20,21, have been developed to investigate cell-type-dependent interactions, physical and chemical perturbations, and the cytotoxic activity of infiltrating lymphocytes22, as well as clinically relevant immunomodulatory agents23.
Here, we provide versatile protocols, spanning from loading cells in chips to image processing tools, to exploit advanced tumor-immune microfluidic co-cultures in 2D (section 1) and 3D (section 2) settings16, compatible with dynamic, multiparametric24 monitoring and visualization of cellular functions. This is achieved maintaining easiness of use and flexibility both in sample management and data analysis, taking advantage of Fiji freeware software and its toolboxes25,26.
The microfluidic device, described in section 1, is designed to perform 2D co-cultures of adherent cancer and floating immune cells. This platform was validated for the in vitro measurement of immune cell behavior in the presence of genetic mutations27 and/or immunodeficiencies28. Here, we illustrate steps for tracking immune cells in time-lapse bright-field images, by exploiting a semi-automatic method based on Trackmate (a plugin implemented in Fiji software). This procedure enables the extraction of kinematic descriptors of immune migration 29 and response (i.e., interaction times) to target cancer cells, treated or not with immunogenic cell death inducers27.
Importantly these parameters, extracted from time-series images, can be processed with advanced mathematical machinery. As an example of the potentiality of this approach, our groups recently published an analysis based on mathematical methods from stochastic processes and statistical mechanics to model cellular network properties and provide a parametrized description of immune cell behavior (i.e., biased or uncorrelated random walk, highly or not coordinated motion30,31).
The 3D setting, provided in the second section, is based on a co-culture protocol to recreate more complex immunocompetent TMEs embedded in two gel regions with different combinations of cell types and drugs in a competitive fashion. Here, image processing steps are described to measure, at different timepoints, the infiltration of stained immune cells in human A375M melanoma cells cultivated within Matrigel, to evaluate antitumor agent combinations32. A375M line, an A375P derived cell line characterized by a highly metastatic phenotype was chosen to evaluate their metastatic capability in the presence of immune cells32.
The described models can be fully compliant with different cell sources (murine and human immortalized or primary cell lines, organoids, xenografts, among the others). In recent studies of our lab, by combining high-content video microscopy with image analysis, the competitive 3D layout was applied to investigate: i) an anti-tumoral (antibody-dependent cell-mediated cytotoxicity, ADCC) immune response and dissect the role of fibroblasts in resistance to trastuzumab therapy in HER2+ breast cancer on-chip models33; ii) the action of myeloid cells (i.e., cancer-associated macrophages) in mechanisms of tumor evasion and recruitment of T cells34; iii) the efficacy of immunotherapeutic regimes, specifically based on Interferon-α-conditioned dendritic cells (IFN-DCs), cultivated with drug-treated colon cancer cells in collagen matrices, and to evaluate efficient motion and the succeeding phagocytosis events35; iv) the chemotactic migration of bone marrow-derived eosinophils towards IL-33 treated or untreated melanoma cells36.
These advanced models could serve as observation windows for understanding the role of immune contexture in cancer metastasis and resistance mechanisms, but efforts are required to translate findings into the clinics, closing the gap with basic research37.
As an emerging scenario, harnessing the power of automated high-content microscopy coupled to the use of more physiologically-relevant microsystems is opening novel potential challenges for the handling, processing, and interpretation of hundreds, and even thousands, of Gigabytes of multiparametric data, which can be generated from a single experimental campaign. This implies a direct link of OOC experiments with artificial intelligence38,39,40,41,42 (AI)-based algorithms both for advanced automated analysis, and generation of features which can feed in turn in silico models of cancer-immune interplay43, with exciting new applications at the horizon, such as the development of predictive drug screening assays44.
An ever-expanding flow of efforts is focused on the design of disease models jointly with the optimization of strategies to implement the large-scale perturbation screens with single-cell multi-omics readouts. This will undoubtedly help the development and, hopefully, the clinical implementation, accompanied by an appropriate degree of method standardization, of a systematic onco-immunology-on-a-chip approach to gain novel insights into immune disorders and cancer dissemination mechanisms.